person · Reporting owner
van der Vaart Sandra D
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortrea Holdings Inc.FTRE · Entity 4623 | Director · President and Secretary | June 20, 2023 | June 21, 2023 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | EVP, Corporate Affairs | March 26, 2026 | March 30, 2026 |
| SEQUENOM INCSQNM · Entity 182543 | Director | September 07, 2016 | September 07, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortrea Holdings Inc.
Report date June 20, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,816 |
Reported balance
After 2023-06-20 transaction · row 1
1 source rowRow 1 · 2023-06-20 · Other · Acquired 7,816 · Balance 7,816 F1: In connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), Labcorp will distribute all of the outstanding shares of Fortrea common stock held by Labcorp to Labcorp common stockholders as of the record date, which was the close of business on June 20, 2023 (the "Record Date"). For each share of Labcorp common stock held on the Record Date, Labcorp will distribute one share of Fortrea common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), Labcorp will distribute all of the outstanding shares of Fortrea common stock held by Labcorp to Labcorp common stockholders as of the record date, which was the close of business on June 20, 2023 (the "Record Date"). For each share of Labcorp common stock held on the Record Date, Labcorp will distribute one share of Fortrea common stock.
LABCORP HOLDINGS INC.
Report date March 26, 2026 · Filed March 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,238.9467 |
Ending reported balance
After 2026-03-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-26 · Grant · Acquired 6,382 · Balance 8,960.9467 F1: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Row 2 · 2026-03-26 · Tax withholding · Disposed 2,722 · Balance 6,238.9467 F2: Stock withholding to satisfy tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.
F2: Stock withholding to satisfy tax withholding obligations.
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · derivative · entry 8 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,877 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 78 | $238.26 | $18,584.28 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,634.0415 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,712.0415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 80 | $238.26 | $19,060.80 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,429.0415 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,509.0415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 20:43 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 109 | $225.85 | $24,617.65 |
DisclosureSEC source: 0001127602-21-004349 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,219.0415 F4 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 30.9407 shares acquired on June 30, 2020 and 36.2220 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:43 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004349 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,167 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:43 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 83 | $223.78 | $18,573.74 |
DisclosureSEC source: 0001127602-21-004349 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,328.0415 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 30.9407 shares acquired on June 30, 2020 and 36.2220 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 20:43 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-004349 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,411.0415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 30.9407 shares acquired on June 30, 2020 and 36.2220 shares acquired on December 31, 2020 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:26 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 2,500 | $0.00 Strike: $233.39 | $0.00 |
DisclosureSEC source: 0001127602-21-004016 · form4.xml · derivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-02-01 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:26 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 710 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-004016 · form4.xml · derivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,467 Underlying: Common Stock · 710 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 13:38 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 435 | $170.00 | $73,950.00 |
DisclosureSEC source: 0001127602-20-021246 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,043.8788 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 14:06 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 436 | $160.33 | $69,903.88 |
DisclosureSEC source: 0001127602-20-020381 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,478.8788 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 14:06 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 436 | $160.33 | $69,903.88 |
DisclosureSEC source: 0001127602-20-020381 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,914.8788 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:39 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,106 | $131.95 | $145,936.70 |
DisclosureSEC source: 0001127602-20-012385 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,350.8788 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:39 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 3,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012385 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,456.8788 F1 · kind: Shares acquired on March 30, 2020, pursuant to a performance award granted on February 7, 2017, relating to performance during the three-year period ended December 31, 2019. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 22:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 103 | $188.49 | $19,414.47 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 6 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,735.8788 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 22:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 105 | $188.49 | $19,791.45 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 5 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,838.8788 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 283 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · derivative · entry 8 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,757 Underlying: Common Stock · 283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F6 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · derivative · entry 7 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,040 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 78 | $187.51 | $14,625.78 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,943.8788 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021.8788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 80 | $187.51 | $15,000.80 |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,738.8788 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 22:11 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-005720 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,818.8788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 18:45 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 133 | $181.99 | $24,204.67 |
DisclosureSEC source: 0001127602-20-004808 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,528.8788 F4 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 37.511 shares acquired on June 28, 2019 and 30.121 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:45 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 367 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004808 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,330 Underlying: Common Stock · 367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F5 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:45 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 101 | $182.33 | $18,415.33 |
DisclosureSEC source: 0001127602-20-004808 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,661.8788 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 37.511 shares acquired on June 28, 2019 and 30.121 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 18:45 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 367 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-004808 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,762.8788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 37.511 shares acquired on June 28, 2019 and 30.121 shares acquired on December 31, 2019 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:34 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 3,600 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-003951 · form4.xml · derivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires 2030-02-03 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 19:34 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-003951 · form4.xml · derivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,637 Underlying: Common Stock · 840 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 23:20 UTC Amendment | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 3,900 | $0.00 Strike: $182.51 | $0.00 |
DisclosureSEC source: 0001127602-20-004425 · form4a.xml · derivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock · 3,900 shares Expires 2030-02-03 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · kind: This amended form is filed to update the number of Employee Stock Options and Restricted Stock Units awarded and set for on Table II. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 04, 2020 Filed Feb 7, 2020 23:20 UTC Amendment | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004425 · form4a.xml · derivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,697 Underlying: Common Stock · 900 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · kind: This amended form is filed to update the number of Employee Stock Options and Restricted Stock Units awarded and set for on Table II. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| July 08, 2019 Filed Jul 10, 2019 13:02 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 2,328 | $176.75 | $411,474.00 |
DisclosureSEC source: 0001127602-19-024268 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,328.2468 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,782 | $154.79 | $275,835.78 |
DisclosureSEC source: 0001127602-19-014720 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,656.2468 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 21:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 5,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014720 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · SVP, Global General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,438.2468 F1 · kind: Shares acquired on April 1, 2019, pursuant to a performance award granted on February 9, 2016, relating to performance during the three-year period ended December 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.